HIV/AIDS in Brazil

Last updated
Brazilian AIDS program logo BrazilAIDSlogo.jpg
Brazilian AIDS program logo

The first AIDS case identified in Brazil was in 1982. Infection rates climbed exponentially throughout the 1980s, and in 1990 the World Bank famously predicted 1,200,000 cases by 2000, approximately double the actual number that was later reported by the Brazilian Ministry of Health and most international organizations. South and Southeast have 75% or more of this infection (Rio Grande do Sul, São Paulo and Rio de Janeiro). The Northeast has 33% of the population but only 10% of AIDS.

Contents

The Brazilian experience is frequently cited as a model for other developing countries facing the AIDS epidemic, including the internationally controversial policies of the Brazilian government such as the universal provision of antiretroviral drugs (ARVs), progressive social policies toward risk groups, and collaboration with non-governmental organizations.

Prevalence

In 2019, Brazil had 920,000 people living with HIV/AIDS. [1] In 2019, 0.60% of the population had HIV/AIDS. [1] In 2019, there were 14,000 deaths from HIV/AIDS. [1]

History

Brazil's first AIDS case was reported in 1982. Brazil's AIDS response was crafted in 1985, just after Brazil had returned from military rule to democracy, at a time when only four AIDS cases had been reported. [2] The Brazilian Ministry of Health laid the groundwork for a National AIDS Control Program (NACP) in 1986. In 1987, it was placed under the aegis of the National AIDS Control Committee, a group composed of scientists and members of civil society organizations. [3] [4]

The program was reorganized again in 1992 with more emphasis on linkages between government and NGOs. [3] [4] AIDS Project I garnered $90 million in domestic funds and a $160 million loan from the World Bank between 1992 and 1998. AIDS Project II was funded by of both domestic funds and a World Bank loan totalling $370 million between 1998 and 2002. [4]

In 1990—a year when more than 10,000 new cases were reported—the World Bank estimated that Brazil would have 1,200,000 in infections by 2000. However, by 2002, there were fewer than 600,000 estimated infections, less than half the prediction. [5]

Government policies

Universal ARV provision

The single most controversial element of the Brazilian HIV/AIDS response remains the free, universal provision of anti-retroviral drugs (ARVs), including protease inhibitors, starting in December 1996 with Law No. 9313/1996. [6] The guidelines for antiretroviral therapy (ART) are formulated annually by a Support Committee which determines the diagnostic guidelines and the contents of the ARV cocktail. [7] In 2003, 125,000 Brazilians received free ART treatment, accounting for 100% of the total registered AIDS cases but only 20% of the estimated AIDS cases. [5]

ART was traditionally considered too expensive in resource-poor settings in developing countries, which are believed to have a poor capacity for adherence to complicated treatments. [8] However, a 2004 study of 322 outpatient services in Brazil—comprising 87,000 patients—found the rate of adherence to be 75%. [9] Some authors also argue that if the decline in hospital admissions and ambulatory care are taken into account, the policy of universal provision of ART has accumulated a net savings of approximately $200 million. [2] [10]

In the context of Brazil, some have challenged the degree to which improvements in public health can be attributed to ART as opposed to other factors. For example, a 2002 World Bank Policy Research Working Paper, states: [11]

The impact caused by the introduction of therapeutic measures, like the antiretrovirals in their different compositions and associations and/or health promotion and protection measured, though evident, has not been completely explored yet.

A 2003 study, using data from diagnoses occurring in Brazil in 1995 and 1996, found that antiretroviral treatment was the single greatest predictor of survival. [12] The authors demonstrate that variables like year of diagnosis, higher education, sexual exposure category, gender, the presence of specific pathogens all appeared to predict survival in a univariate analysis; however, in a multivariate analysis only antiretroviral treatment, diagnostic criteria, and transmission category remained significant. [13] The authors conclude that no factor other than ART "could reasonably explain the very large increase in survival observed" between the 1980s and 1996. [14]

Social policies

Brazil's response has been characterized by reaching out to groups which account for a high percentage of AIDS transmission, including relationships with non-governmental organizations. For example, in contrast to many parts of the world, condoms were prioritized early and aggressively. Condom use in first sexual intercourse increased from 4% in 1986 to 48% in 1999 and to 55% in 2003, spurred by government programs to increase awareness, decrease the price, and increase the availability of condoms. [5] [15]

Prostitute groups were involved in the distribution of information materials and condoms. [16] Similarly, needle exchange programs were implemented. The prevalence of HIV among injecting drug users (IDUs) fell from 52% in 1999 to 41.5% in 2001. 12 needle exchange programs were implemented between 1994 and 1998; 40 had been implemented by 2000, distributing 1,500,000 syringes in just a year. [15] HIV prevalence among IDU decreased even more dramatically in some cities. [15]

In 1988 comprehensive screening tests were implemented nationwide in blood banks, following a similar program in São Paulo in 1986. The results of these programs were not realized fully until 2000 as a result of the incubation period of the virus, but new cases from blood transfusion became virtually non-existent at that time and new and more effective nucleic acid testing is being considered. [15] [17] Mother-to-child transmission was similarly practically eradicated, falling to a transmission rate of 3%, a level comparable to most developed countries, with the implementation of zidovudine treatment regimes to mother and child and recommendations against breastfeeding. [18]

International conflict

Drug patents

The average annual cost of ART per patient in 1997 was $4,469—compared to over $10,000 in most of the developed world—totaling only $242 million per annum. [19] However, in 2001, Brazil manufactured locally 8 of the 12 drugs in the national ARV cocktail; in 2003 and 2005, 8 of the 15. [20] [21] If all of the drugs were patented imports, the cost of these ARV programs would increase by 32%. [19] Between 1996 and 2000, Brazil reduced treatment costs by 72.5% through import substitution. By contrast, the price of imports dropped by only 9.6%. [20] Brazil has saved over US$1.1 billion in the cost of providing universal access to ART by producing anti-retroviral medications generically. [22]

Article 71 of the 1997 Brazilian patent law requires that foreign products be manufactured in Brazil within three years of receiving a patent. If a foreign company does not comply, Brazil may authorize a local company to produce the drug without the consent of the patent holder, a tactic known as "compulsory licensing" or the "bargaining chip and as a last resort." [23] In addition, Article 68 authorizes "parallel importing" from the lowest international generic bidder, effectively destroying the patent holder's monopoly as well. [24]

Prodded by domestic pharmaceutical lobbies, the U.S. challenged Article 68 within the framework of the World Trade Organization's Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPs) regime for allegedly discriminating against imported products; Article 71—to the chagrin of many companies—was not included in the complaint. In addition, the U.S. placed Brazil on the "Special 301" watch list, opening the possibility for "unilateral sanctions," and companies individually threatened to pull out of the Brazilian market altogether. [25]

Brazil argued that the law only applied to cases where the patent holder abuses their economic power, a loophole specifically allowed by the TRIPS agreement. [20] Advocates of intellectual property rights (IPR) worldwide condemned the actions of the Brazilian government. For example, Slavi Pachovski, a member of the Institute for Trade, Standards and Sustainable Development, argues: [26]

If this trend proceeds, it will be a global pandemic of AIDS that will grow uncontrollable because the Brazilian move will destroy the whole legal order that is the basis for developing new drugs and continuing research.

The pharmaceutical companies were not just afraid of the immediate loss of the Brazilian market, but with the larger implications of other developing countries following Brazil's example. Large developing countries, like India, with large industrial capacities and evolving intellectual property regimes are the true elephant in the room. [27]

Brazil invoked the Article 71 for the first time on August 22, 2001, when José Serra, Brazil's Minister of Health, authorized Far Manguinhos—a Brazilian pharmaceutical company—to produce Nelfinavir, a drug patented by Pfizer but licensed to Roche in the Brazilian market. This unilateral action prompted a flurry of negotiations where Roche and Merck agreed to reduce the prices of five drugs by 40-65%. An advertisement distributed by the Brazilian government proclaimed: "Local manufacturing of many of the drugs used in the anti-AIDS cocktail is not a declaration of war against the drugs industry. It is simply a fight for life." [28]

Brazil carried out such a compulsory licensing threat for the first time in May 2007, on efavirenz, produced by Merck. [29]

The agreements signed on November 14, 2001, at the WTO conference in Qatar reaffirmed that TRIPs "does not and should not prevent Members from taking measures to protect public health" including "medicines for all." [20] That same year, the United Nations Commission on Human Rights affirmed access to AIDS drugs as a human right unanimously, with the exception of the abstention of the United States.[ citation needed ]

Prostitution

Two 2003 United States laws—one related to AIDS, the other to sex trafficking—required all recipients of U.S. assistance to sign a pledge denouncing prostitution, even if U.S. funds are not used for projects directly related to prostitution. [30] In 2005, Brazil wrote to the United States Agency for International Development (USAID) declining to condemn prostitution, effectively rejecting the remainder of a grant for $48 million between 2003 and 2006. [30] In 2006, USAID officially declared Brazil ineligible to renew the AIDS prevention grant because Brazil would not condemn prostitution as "dehumanizing and degrading." [31]

Brazil considered its partnerships with prostitutes—in distributing contraceptives, educating the public about the disease, and voluntary testing—critical to its overall AIDS prevention strategy. One Ministry of Health pamphlet depicts a character, "Maria Sem Vergonha" (Portuguese for "Maria that knows No Shame", but also a pun on the Brazilian name of the flowering genera " Impatiens spp.", maria-sem-vergonha), a scantily-clad sex worker who encourages prostitutes to take pride in their work and use condoms. [31]

Pedro Chequer, director of Brazil's National AIDS Control Programme, was quoted as saying "we can’t control [the disease] with principles that are Manichaean, theological, fundamentalist and Shiite" [30] and "sex workers are part of implementing our AIDS policy and deciding how to promote it. They are our partners. How could we ask prostitutes to take a position against themselves?" [32] Despite the fact that Brazil has the largest population of Roman Catholics in the world, the Brazilian Roman Catholic Church has not demanded the abstinence-only prevention strategies, voicing only intermittent "mild complaints" about government programs which refuse to acknowledge moral or religious issues. [31]

A "Brazilian model"

Brazil's Health Minister, José Serra, said in 2001, "Our example could serve as a model for other countries in Latin America, the Caribbean, even Africa. Everyone in the world has the right to access these therapies." [33] Some scholars, such as Levi and Vitória, argue that the Brazilian model can only be applied to other countries with similar level of economic development and civil society sectors. [34] Galvão argues that the unique local conditions in Brazil complicate the application of the Brazilian experience to other regions with their own local problems and structures. [35]

A Washington Post article stated that the Brazilian anti-AIDS program is considered by the United Nations to be the most successful in the developing world, [16] and The Economist echoed this position: [16] "no developing country has had more success in tackling AIDS than Brazil.

See also

Related Research Articles

<span class="mw-page-title-main">Treatment Action Campaign</span> South African HIV/AIDS activist organization

The Treatment Action Campaign (TAC) is a South African HIV/AIDS activist organisation which was co-founded by the HIV-positive activist Zackie Achmat in 1998. TAC is rooted in the experiences, direct action tactics and anti-apartheid background of its founder. TAC has been credited with forcing the reluctant government of former South African President Thabo Mbeki to begin making antiretroviral drugs available to South Africans.

HIV/AIDS has been a public health concern for Latin America due to a remaining prevalence of the disease. In 2018 an estimated 2.2 million people had HIV in Latin America and the Caribbean, making the HIV prevalence rate approximately 0.4% in Latin America.

<span class="mw-page-title-main">HIV/AIDS</span> Spectrum of conditions caused by HIV infection

HIV(human immunodeficiency virus) is a retrovirus that attacks the immune system. It can be managed with treatment. Without treatment it can lead to a spectrum of conditions including AIDS (acquired immunodeficiency syndrome).

HIV/AIDS in China can be traced to an initial outbreak of the human immunodeficiency virus (HIV) first recognized in 1989 among injecting drug users along China's southern border. Figures from the Chinese Center for Disease Control and Prevention, World Health Organization, and UNAIDS estimate that there were 1.25 million people living with HIV/AIDS in China at the end of 2018, with 135,000 new infections from 2017. The reported incidence of HIV/AIDS in China is relatively low, but the Chinese government anticipates that the number of individuals infected annually will continue to increase.

Kenya has a severe, generalized HIV epidemic, but in recent years, the country has experienced a notable decline in HIV prevalence, attributed in part to significant behavioral change and increased access to ARV. Adult HIV prevalence is estimated to have fallen from 10 percent in the late 1990s to about 4.8 percent in 2017. Women face considerably higher risk of HIV infection than men but have longer life expectancies than men when on ART. The 7th edition of AIDS in Kenya reports an HIV prevalence rate of eight percent in adult women and four percent in adult men. Populations in Kenya that are especially at risk include injecting drug users and people in prostitution, whose prevalence rates are estimated at 53 percent and 27 percent, respectively. Men who have sex with men (MSM) are also at risk at a prevalence of 18.2%. Other groups also include discordant couples however successful ARV-treatment will prevent transmission. Other groups at risk are prison communities, uniformed forces, and truck drivers.

<span class="mw-page-title-main">HIV/AIDS in Malawi</span> Impact of the immunodeficiency virus in the African nation

As of 2012, approximately 1,100,000 people in Malawi are HIV-positive, which represents 10.8% of the country's population. Because the Malawian government was initially slow to respond to the epidemic under the leadership of Hastings Banda (1966–1994), the prevalence of HIV/AIDS increased drastically between 1985, when the disease was first identified in Malawi, and 1993, when HIV prevalence rates were estimated to be as high as 30% among pregnant women. The Malawian food crisis in 2002 resulted, at least in part, from a loss of agricultural productivity due to the prevalence of HIV/AIDS. Various degrees of government involvement under the leadership of Bakili Muluzi (1994–2004) and Bingu wa Mutharika (2004–2012) resulted in a gradual decline in HIV prevalence, and, in 2003, many people living in Malawi gained access to antiretroviral therapy. Condoms have become more widely available to the public through non-governmental organizations, and more Malawians are taking advantage of HIV testing services.

<span class="mw-page-title-main">HIV/AIDS in Mozambique</span>

Mozambique is a country particularly hard-hit by the HIV/AIDS epidemic. According to 2008 UNAIDS estimates, this southeast African nation has the 8th highest HIV rate in the world. With 1,600,000 Mozambicans living with HIV, 990,000 of which are women and children, Mozambique's government realizes that much work must be done to eradicate this infectious disease. To reduce HIV/AIDS within the country, Mozambique has partnered with numerous global organizations to provide its citizens with augmented access to antiretroviral therapy and prevention techniques, such as condom use. A surge toward the treatment and prevention of HIV/AIDS in women and children has additionally aided in Mozambique's aim to fulfill its Millennium Development Goals (MDGs). Nevertheless, HIV/AIDS has made a drastic impact on Mozambique; individual risk behaviors are still greatly influenced by social norms, and much still needs to be done to address the epidemic and provide care and treatment to those in need.

With less than 0.1 percent of the population estimated to be HIV-positive, Bangladesh is a low HIV-prevalence country.

The Philippines has one of the lowest rates of infection of HIV/AIDS, yet has one of the fastest growing number of cases worldwide. The Philippines is one of seven countries with growth in number of cases of over 25%, from 2001 to 2009.

Since HIV/AIDS was first reported in Thailand in 1984, 1,115,415 adults had been infected as of 2008, with 585,830 having died since 1984. 532,522 Thais were living with HIV/AIDS in 2008. In 2009 the adult prevalence of HIV was 1.3%. As of 2016, Thailand had the highest prevalence of HIV in Southeast Asia at 1.1 percent, the 40th highest prevalence of 109 nations.

Cases of HIV/AIDS in Peru are considered to have reached the level of a concentrated epidemic.

HIV/AIDS in El Salvador has a less than 1 percent prevalence of the adult population reported to be HIV-positive. El Salvador therefore is a low-HIV-prevalence country. The virus remains a significant threat in high-risk communities, such as commercial sex workers (CSWs) and men who have sex with men (MSM).

Honduras is the Central American country most adversely affected by the HIV/AIDS epidemic. It is estimated that the prevalence of HIV among Honduran adults is 1.5%.

<span class="mw-page-title-main">HIV/AIDS in Haiti</span>

With an estimated 150,000 people living with HIV/AIDS in 2016, Haiti has the most overall cases of HIV/AIDS in the Caribbean and its HIV prevalence rates among the highest percentage-wise in the region. There are many risk-factor groups for HIV infection in Haiti, with the most common ones including lower socioeconomic status, lower educational levels, risky behavior, and lower levels of awareness regarding HIV and its transmission.

The Catholic Church is a major provider of medical care to HIV/AIDS patients. Much of its work takes place in developing countries, although it has also had a presence in the global north. Its opposition to condoms, despite their effectiveness in preventing the spread of HIV, has invited criticism from public health officials and anti-AIDS activists.

HIV drug resistance occurs when microevolution causes virions to become tolerant to antiretroviral treatments (ART). ART can be used to successfully manage HIV infection, but a number of factors can contribute to the virus mutating and becoming resistant. Drug resistance occurs as bacterial or viral populations evolve to no longer respond to medications that previously worked. In the case of HIV, there have been recognized cases of treatment resistant strains since 1989, with drug resistance being a major contributor to treatment failure. While global incidence varies greatly from region to region, there has been a general increase in overall HIV drug resistance. The two main types of resistance, primary and induced, differ mostly in causation, with the biggest cause of resistance being a lack of adherence to the specific details of treatment. These newly created resistant strains of HIV pose a public health issue as they infect a growing number of people because they are harder to treat, and can be spread to other individuals. For this reason, the reaction to the growing number of cases of resistant HIV strains has mostly been to try to increase access to treatment and implement other measures to make sure people stay in care, as well as to look into the development of an HIV vaccine or cure.

HIV prevention refers to practices that aim to prevent the spread of the human immunodeficiency virus (HIV). HIV prevention practices may be undertaken by individuals to protect their own health and the health of those in their community, or may be instituted by governments and community-based organizations as public health policies.

The cost of HIV treatment is a complicated issue with an extremely wide range of costs due to varying factors such as the type of antiretroviral therapy and the country in which the treatment is administered. The first line therapy of HIV, or the initial antiretroviral drug regimen for an HIV-infected patient, is generally cheaper than subsequent second-line or third-line therapies. There is also a great variability of drug prices among low, middle, and high income countries. In general, low-income countries have the lowest cost of antiretroviral therapy, while middle- and high-income tend to have considerably higher costs. Certain prices of HIV drugs may be high and difficult to afford due to patent barriers on antiretroviral drugs and slow regulatory approval for drugs, which may lead to indirect consequences such as greater HIV drug resistance and an increased number of opportunistic infections. Government and activist movements have taken efforts to limit the price of HIV drugs.

Treatment as prevention (TasP) is a concept in public health that promotes treatment as a way to prevent and reduce the likelihood of HIV illness, death and transmission from an infected individual to others. Expanding access to earlier HIV diagnosis and treatment as a means to address the global epidemic by preventing illness, death and transmission was first proposed in 2000 by Garnett et al. The term is often used to talk about treating people that are currently living with human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS) to prevent illness, death and transmission. Although some experts narrow this to only include preventing infections, treatment prevents illnesses such as tuberculosis and has been shown to prevent death. In relation to HIV, antiretroviral therapy (ART) is a three or more drug combination therapy that is used to decrease the viral load, or the measured amount of virus, in an infected individual. Such medications are used as a preventative for infected individuals to not only spread the HIV virus to their negative partners but also improve their current health to increase their lifespans. When taken correctly, ART is able to diminish the presence of the HIV virus in the bodily fluids of an infected person to a level of undetectability. Consistent adherence to an ARV regimen, monitoring, and testing are essential for continued confirmed viral suppression. Treatment as prevention rose to great prominence in 2011, as part of the HPTN 052 study, which shed light on the benefits of early treatment for HIV positive individuals.

<span class="mw-page-title-main">Michel Alary</span> Canadian academic, doctor

Michel Alary is a Canadian academic, doctor of preventive medicine and a health researcher. He is a Professor of Social and Preventive Medicine at Université Laval and the director of population health research at the Research Centre of the CHU de Quebec – Université Laval. He also serves as a Medical Consultant at the Institut national de santé publique du Québec. Alary has published over 260 research papers and has produced major reports for the World Bank and UNAIDS about HIV in sub-Saharan Africa. He also evaluated the Bill & Melinda Gates Foundation's India AIDS Initiative for which his project received the Avahan Recognition Award. He has conducted epidemiological and preventive research on blood-borne infections, HIV and other Sexually Transmitted Diseases (STD) among the most vulnerable populations in developed and developing countries.

References

Notes

  1. 1 2 3 Daniels, J. P. (2020-12-01). "COVID-19 threatens HIV care continuity in Brazil". The Lancet. HIV. 7 (12): e804–e805. doi: 10.1016/S2352-3018(20)30312-X . PMID   33275915. S2CID   227296365.
  2. 1 2 Teixeira et al., 2004, S6.
  3. 1 2 Levi and Vitória, 2002, p. 2373
  4. 1 2 3 Levi and Vitória, 2002, p. 2374.
  5. 1 2 3 Ministry of Health of Brazil, 2003.
  6. ↑ Castilho, Selma Rodrigues de; Brito, Monique Araújo de; Piccoli, Nilo Jorge; Castilho, Selma Rodrigues de; Brito, Monique Araújo de; Piccoli, Nilo Jorge (2017). "Assessment of pharmaceutical services in HIV/AIDS health units in the city of Niterói, Brazil". Brazilian Journal of Pharmaceutical Sciences. 53 (2). doi: 10.1590/s2175-97902017000216113 . ISSN   1984-8250.
  7. ↑ Levi and Vitória, 2002, p. 2378.
  8. ↑ Colebunders et al., 2000.
  9. ↑ Nemes et al., 2004, S15.
  10. ↑ Teixeira et al.,2004, S7.
  11. ↑ Novaes et al., 2002, p. 10
  12. ↑ Marins et al., 2003, p. 1675.
  13. ↑ Marins et al., 2003, p. 1678-1680.
  14. ↑ Marins et al., 2000, p. 1681.
  15. 1 2 3 4 Levi and Vitória, 2002, p. 2375.
  16. 1 2 3 Where Prostitutes Also Fight AIDS, Washington Post , 2 March 2006
  17. ↑ Levi and Vitória, 2002, p. 2376.
  18. ↑ Levi and Vitória, 2002, p. 2377.
  19. 1 2 Szwarcwald, 2002.
  20. 1 2 3 4 Gilman, 2001; Brazilian National STD/AIDS Programme, 2003
  21. ↑ Gentile, 2005.
  22. ↑ Berkman, Alan; Jonathan Garcia; Miguel Munox-Laboy; Vera Paiva; Richard Parker (2005). "A Critical Analysis of the Brazilian Response to HIV/AIDS: Lessons Learned for Controlling and Mitigating the Epidemic in Developing Countries". American Journal of Public Health. 95 (7): 1162–1172. doi:10.2105/ajph.2004.054593. PMC   1449335 . PMID   15933232.
  23. ↑ Oxfam GB, 2001, p. 6.
  24. ↑ Oxfam GB, 2001, p. 10-11.
  25. ↑ Oxfam GB, 2001, p. 3.
  26. ↑ Pachovski, 2005.
  27. ↑ Oxfam GB, 2001, p. 2.
  28. ↑ quoted in Wadia, 2001.
  29. ↑ The Economist . May 12, 2007. "Brazil's AIDS programme: A conflict of goals." p. 42.
  30. 1 2 3 Phillips and Moffett, 2005.
  31. 1 2 3 Reel, 2006.
  32. ↑ Just Say Não Archived 2010-04-16 at the Wayback Machine , The Nation , 12 May 2005
  33. ↑ Wadia, 2001.
  34. ↑ Levi and Vitória, 2002.
  35. ↑ Galvão, 2002
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.